UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Clinical cancer research, 2011-12, Vol.17 (24), p.7614-7624

2011

Volltextzugriff (PDF)

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

Proceedings of the National Academy of Sciences - PNAS, 2007-03, Vol.104 (10), p.4106-4111

2007

Volltextzugriff (PDF)

MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo

Molecular cancer research, 2010-03, Vol.8 (3), p.373-384

2010

Volltextzugriff (PDF)

Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)

Molecular cancer therapeutics, 2014-09, Vol.13 (9), p.2170-2183

2014

Volltextzugriff (PDF)

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Cancer medicine (Malden, MA), 2024-03, Vol.13 (5), p.n/a

2024

Volltextzugriff (PDF)

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

ACS medicinal chemistry letters, 2015-06, Vol.6 (6), p.630-634

2015

Volltextzugriff (PDF)

Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma

mSphere, 2018-08, Vol.3 (4)

2018

Volltextzugriff (PDF)

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2567-2567

2018

Volltextzugriff (PDF)

The Syk Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of EBV-Associated Lymphoma

Blood, 2016-12, Vol.128 (22), p.4179-4179

2016

Volltextzugriff (PDF)

Anti-tumor activity of TAK-659, a dual inhibitor of SYK and FLT-3 kinases, in AML models

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14091-e14091

2016

Volltextzugriff (PDF)

Abstract A164: The small molecule UAE inhibitor TAK-243 (MLN7243) prevents DNA damage repair and reduces cell viability/tumor growth when combined with radiation, carboplatin and docetaxel

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A164-A164

2015

Volltextzugriff (PDF)

Abstract B189: MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B189-B189

2013

Volltextzugriff (PDF)

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

Cancer chemotherapy and pharmacology, 2013-12, Vol.72 (6), p.1255-1264

2013

Volltextzugriff (PDF)

Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8580-8580

2014

Volltextzugriff (PDF)

The Investigational Aurora A Kinase Inhibitor MLN8237 in Combination with Vincristine Demonstrates Robust Anti-Tumor Activity in Preclinical B-Cell Non-Hodgkin's Lymphoma Models

Blood, 2011-11, Vol.118 (21), p.2733-2733

2011

Volltextzugriff (PDF)

Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell Lymphoma Preclinical Models

Blood, 2008-11, Vol.112 (11), p.1592-1592

2008

Volltextzugriff (PDF)

Abstract C82: Identification and preclinical characterization of inhibitors of the ubiquitin-activating enzymes UBA1 and UBA6

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C82-C82

2011

Volltextzugriff (PDF)

Lewy Body–like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α‐Synuclein Mutations

Annals of neurology, 2021-09, Vol.90 (3), p.490-505

2021

Volltextzugriff (PDF)

Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity

Cardiovascular research, 2018-02, Vol.114 (2), p.282-290

2018

Volltextzugriff (PDF)

A novel treatment modality for myogenous temporomandibular disorders using aromatherapy massage with lavender oil: A randomized controlled clinical trial

Cranio, 2023-01, Vol.41 (1), p.48-58

2023

Volltextzugriff (PDF)

Diverse functional autoantibodies in patients with COVID-19

Nature (London), 2021-07, Vol.595 (7866), p.283-288

2021

Volltextzugriff (PDF)

Endothelial cell mineralocorticoid receptors oppose VEGF-induced gene expression and angiogenesis

Journal of endocrinology, 2019-01, Vol.240 (1), p.15-26

2019

Volltextzugriff (PDF)

Sociodemographic Characteristics, Health Conditions, and Functional Impairment Among Older Adults With Serious Mental Illness Reporting Moderate-to-Severe Pain

Psychiatric rehabilitation journal, 2018-09, Vol.41 (3), p.224-233

2018

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)
Buchkapitel
(2)

Sprache

Englisch
(29)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(14)
Humans
(13)
Animals
(10)
Female
(9)
Mice
(9)
Cell Line, Tumor
(6)
Male
(6)
Mice, Nude
(5)
Oncology
(5)
Antineoplastic Agents
(3)
Antineoplastic Agents - Pharmacology
(3)
Aurora Kinase A
(3)
Aurora Kinases
(3)
Disease Models, Animal
(3)
Hct116 Cells
(3)
Pain
(3)
Protein-Serine-Threonine Kinases - Antagonists & Inhibitors
(3)
Pyrimidines - Pharmacology
(3)
Science & Technology - Other Topics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo

Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models

The Syk Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of EBV-Associated Lymphoma

Anti-tumor activity of TAK-659, a dual inhibitor of SYK and FLT-3 kinases, in AML models

Abstract A164: The small molecule UAE inhibitor TAK-243 (MLN7243) prevents DNA damage repair and reduces cell viability/tumor growth when combined with radiation, carboplatin and docetaxel

Abstract B189: MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models

The Investigational Aurora A Kinase Inhibitor MLN8237 in Combination with Vincristine Demonstrates Robust Anti-Tumor Activity in Preclinical B-Cell Non-Hodgkin's Lymphoma Models

Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell Lymphoma Preclinical Models

Abstract C82: Identification and preclinical characterization of inhibitors of the ubiquitin-activating enzymes UBA1 and UBA6

Lewy Body–like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α‐Synuclein Mutations

Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity

A novel treatment modality for myogenous temporomandibular disorders using aromatherapy massage with lavender oil: A randomized controlled clinical trial

Diverse functional autoantibodies in patients with COVID-19

Endothelial cell mineralocorticoid receptors oppose VEGF-induced gene expression and angiogenesis

Nano‐in‐Microparticles for Aerosol Delivery of Antibiotic‐Loaded, Fucose‐Derivatized, and Macrophage‐Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery

Sociodemographic Characteristics, Health Conditions, and Functional Impairment Among Older Adults With Serious Mental Illness Reporting Moderate-to-Severe Pain

Suchergebnisse filtern